The ALS8 protein VAPB interacts with the ER–Golgi recycling protein YIF1A and regulates membrane delivery into dendrites

Marijn Kuijpers1,2, Ka Lou Yu1,2, Eva Teuling3, Anna Akhmanova1, Dick Jaarsma2 and Casper C Hoogenraad1,2,*

1Division of Cell Biology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands and 2Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands

The vesicle-associated membrane protein (VAMP) associated protein B (VAPB) is an integral membrane protein localized to the endoplasmic reticulum (ER). The P56S mutation in VAPB has been linked to motor neuron degeneration in amyotrophic lateral sclerosis type 8 (ALS8) and forms ER-like inclusions in various model systems. However, the role of wild-type and mutant VAPB in neurons is poorly understood. Here, we identified Yip1-interacting factor homologue A (YIF1A) as a new VAPB binding partner and important component in the early secretory pathway. YIF1A interacts with VAPB via its transmembrane regions, recycles between the ER and Golgi and is mainly localized to the ER–Golgi intermediate compartments (ERGICs) in rat hippocampal neurons. VAPB strongly affects the distribution of YIF1A and is required for intracellular membrane trafficking into dendrites and normal dendritic morphology. When VAPB-P56S is present, YIF1A is recruited to the VAPB-P56S clusters and loses its ERGIC localization. These data suggest that both VAPB and YIF1A are important for ER-to-Golgi transport and that missorting of YIF1A may contribute to VAPB-associated motor neuron disease.

The EMBO Journal (2013) 32, 2056–2072. doi:10.1038/emboj.2013.131; Published online 4 June 2013

Subject Categories: membranes & transport; neuroscience

Keywords: amyotrophic lateral sclerosis (ALS); dendrite morphology; secretory pathway; VAMP-associated protein (VAP); Yip1 interacting factor (YIF1)

Introduction

The secretory pathway is responsible for the delivery of a variety of protein and lipid cargo, such as ion channels, receptors and lipid membranes, to their proper location. In the early secretory pathway, newly synthesized proteins that pass the quality control of the endoplasmic reticulum (ER) concentrate at specialized ER subdomains called the ER exit sites (ERES) (Lee et al., 2004; Dancourt and Barlowe, 2010).

From here, cargo leaves the ER and is transported to the Golgi compartments to undergo further processing, sorting and subsequent delivery to the plasma membrane or other cellular organelles. ER-derived vesicles deliver their cargo either directly to the cis-Golgi membrane or pass a specialized membrane compartment called the ER–Golgi intermediate compartment (ERGIC) (Watson and Stephens, 2005; Appenzeller-Herzog and Hauri, 2006; Saraste et al., 2009; Lorente-Rodriguez and Barlowe, 2011). Whereas the early secretory pathway and its organization is well studied in a variety of cellular model systems such as yeast and fibroblasts, little information is available about this trafficking pathway in neuronal cells. A number of studies have demonstrated the presence of ER-to-Golgi transport components in neurons (Krijnse-Locker et al., 1995; Pierce et al., 2001; Horton and Ehlers, 2003) and indicated the importance of the early secretory trafficking for neuronal development and morphogenesis (Hanus and Ehlers, 2008; Tang, 2008; Aridor and Fish, 2009; Jan and Jan, 2010).

Members of the highly conserved VAP family, including the mammalian vesicle-associated membrane protein associated protein A (VAPA) and VAPB proteins, are present in the ER and have been proposed to play a role in maintaining Golgi complex identity, ER morphology, lipid transfer and in regulating ER and Golgi transport (Soussan et al., 1999; Skehel et al., 2000; Pennetta et al., 2002; Amarillo et al., 2005; Teuling et al., 2007; Lev et al., 2008; Peretti et al., 2008; Tsuda et al., 2008; Han et al., 2012). VAP proteins contain an N-terminal domain, which is highly homologous to the nematode major sperm protein (MSP), a central domain that forms a coiled-coil structure and the C-terminal transmembrane tail domain (Nishimura et al., 1999; Kaiser et al., 2005). Interest in VAP proteins has greatly increased after the discovery of a dominant missense mutation P56S in the MSP domain of VAPB, which causes a familial motor neuron disease, designated amyotrophic lateral sclerosis type 8 (ALS8) (Nishimura et al., 2004). P56S mutant VAPB accumulates in inclusions that contain abnormal organized ER (Teuling et al., 2007; Papiani et al., 2012) and recruit wild-type VAPA/VB in these inclusions, suggesting that VAPB-P56S could have a dominant-negative effect on VAP function (Teuling et al., 2007). Indeed, a loss-of-function mechanism has been observed in several model systems (Chai et al., 2008; Ramaparkhi et al., 2008; Tsuda et al., 2008; Suzuki et al., 2009; Forrest et al., 2013). Moreover, a reduction in VAP protein levels has been described in sporadic ALS patients, SOD1 mutant mice as well as ALS-derived motor neurons (Teuling et al., 2007; Anagnostou et al., 2010; Mitne-Neto et al., 2011). However, mechanisms leading to VAPB-linked motor neuron degeneration are still poorly understood.

To gain more insight into the role of VAPB in neurons, we searched for new binding partners of VAPB. We identified Yip1-interacting factor homologue A (YIF1A) as a new VAPB
binding partner that interacts with both wild-type VAPB and mutant VAPB-P56S. YIF1A is the human orthologue of the budding yeast Yif1p, a transmembrane protein that plays an important role in early secretory transport in yeast and mammalian cells (Matern et al., 2000; Barrowman et al., 2003; Jin et al., 2005; Yoshida et al., 2008). We find that YIF1A recycles between the ER and Golgi and is mainly localized to the ERGIC in hippocampal neurons. Both VAPB and YIF1A are required for membrane trafficking to dendrites and proper dendrite morphology. In addition, we show that ALS8 mutant VAPB-P56S strongly disrupts the localization of YIF1A to ERGIC. Our data suggest an important role for YIF1A and VAPB in the early secretory pathway and we propose that the missorting of YIF1A plays a role in VAPB-associated motor neuron disease. These findings advance the knowledge of fundamental trafficking processes in neuronal cells and have important implications for our understanding of neuronal degeneration.

**Results**

**YIF1A interacts with both wild-type and mutant VAPB**

To identify new VAPB interacting proteins, we performed pull-down assays combined with mass spectrometry. Biotinylated and GFP-tagged VAPB (bio-GFP-VAPB) and control bio-GFP constructs were transiently co-expressed in HEK293T cells together with the protein-biotin ligase BirA, isolated with streptavidin beads and the proteins were analysed by mass spectrometry. Bio-GFP-VAPB bound to several previously identified VAPB binding partners, such as the FFAT-motif containing proteins N1R2, OSBP3, OSBPL6 and OSBPL9 (Wyles and Ridgway, 2004; Amarilio et al., 2005; Lehto et al., 2005; Teuling et al., 2007) (Figure 1A). In addition, a novel potential VAPB binding partner was identified, YIF1A, a transmembrane protein of 293 amino acids and mammalian orthologue of the *Saccharomyces cerevisiae* protein Yip1p (Yip1p-interacting factor 1) (Matern et al., 2000). YIF1A and its close homologue YIF1B are members of a large protein family, named FinGERS, which share a common structure with an N-terminal hydrophilic region, followed by conserved transmembrane regions (Shakoori et al., 2003; Pfeffer and Aivazian, 2004).

The interaction of VAPB and YIF1A was confirmed by biotin pull-down experiments using extracts of HEK293T cells overexpressing GFP-YIF1A and bio-HA-VAPB (Figure 1B). Pull-down experiments also revealed binding between YIF1B and VAPB (Figure 1B) and between VAPA and both YIF homologues (Figure 1C). To further confirm the interaction between VAPB and YIF1A, we performed immuno-fluorescence experiments in COS-7 cells. HA-YIF1A co-localized with both endogenous VAPB and co-transfected myc-VAPB, which as previously demonstrated localize to the ER (Nishimura et al., 2004; Kanekura et al., 2006; Teuling et al., 2007; Kim et al., 2010; Papiani et al., 2012) (Figure 1D and E). Significantly, HA-YIF1A also co-distributes with ALS-linked mutant VAPB-P56S and VAPA-P56S (Figure 1F and H), which accumulate in small spherical inclusions (Nishimura et al., 2004; Kanekura et al., 2006; Teuling et al., 2007; Kim et al., 2010; Papiani et al., 2012). Likewise also YIF1B was recruited to mutant VAPA/B inclusion (Figure 1G and I). Together, these results show that YIF1A/B interacts with VAPA/B family proteins.

**The transmembrane domains of both VAPB and YIF1A are required for their interaction**

Secondary structure predictions indicate that YIF1A contains four transmembrane domains at the C-terminus (Figure 2A) (Altschul et al., 1997; Hirokawa et al., 1998), while the N-terminus of the yeast homologue Yif1p has been shown to face the cytosol (Matern et al., 2000). To confirm that the N-terminus of YIF1A faces the cytosol, we generated a YIF1A construct with a biotinylation tag at the N-terminus (Figure 2B). Pull-down experiments showed that this construct was biotinylated when the biotinylating enzyme BirA was localized in the cytoplasm, but not by a variant BirA that is localized in the ER lumen (Figure 2B).

To identify the regions through which YIF1A interacts with VAPB, we first made truncated GFP-YIF1A constructs encoding either the N-terminus (1–131) or the C-terminal transmembrane region (131–293) of YIF1A (Figure 2A). Pull-down experiments using HEK293T cells co-expressing HA-VAPB and the YIF1A deletion constructs showed that VAPB only co-precipitated with YIF1A construct that contained the transmembrane region (Figure 2C and D). These data were confirmed by a glutathione S-transferase (GST) pull-down assay with cell lysates expressing truncated YIF1A constructs using VAPB and VAPB-P56S immobilized on GST beads. The C-terminal part, but not the N-terminal part of YIF1A co-precipitated with VAPB and VAPB-P56S (Figure 2E). To characterize in more detail the YIF1A domain that binds VAPB, we made additional truncated YIF1A constructs, which contain only the first two transmembrane domains (131–198), the last two transmembrane domains (198–298) or the N-terminal cytosolic domain with the first two transmembrane domains (1–198) (Figure 2A). Pull-down experiments with biotinylated VAPB showed that all transmembrane containing YIF1A constructs co-precipitated with VAPB (Figure 2F). However, VAPB brings down considerable higher amounts of truncated GFP-YIF1A proteins that contain the first and second transmembrane domain (131–198) (Figure 2F), indicating that the VAPB interaction is strongest with this region. The marked difference between binding of the first two transmembrane domains compared to the last two transmembrane domains suggests a specific interaction between YIF1A and VAPB. GFP-YIF1A (131–198) also efficiently co-precipitated with VAPB-P56S (Figure 2G). Moreover, the GFP-tagged single transmembrane domain of VAPB co-immunoprecipitates with YIF1A, suggesting that the transmembrane domain of VAPB is important for binding YIF1A (Figure 2H). To further explore the binding of YIF1A with VAPB, we mutated two GxxG motifs that are present in the first and third transmembrane domain of YIF1A (Figure 2A). GxxG motifs are known to facilitate interactions between transmembrane helices and mediate the assembly of the transmembrane helices in VAPB (Kim et al., 2010). However, disruption of these motifs in YIF1A did not interfere with VAPB binding (Figure 2I). These data were confirmed by immuno-fluorescence in COS-7 cells (Figure 2J–L; Supplementary Figure S1). The results show that the first two transmembrane domains of YIF1A are important for VAPB binding but that this binding does not depend on GxxG motifs. Together, these data indicate that the transmembrane domains of both VAPB and YIF1A are important for their interaction.
YIF1A recycles between the Golgi and ER and localizes to the ERGIC in hippocampal neurons

Next, we investigated the function of the VAPB–YIF1A interaction using primary cultured rat hippocampal neurons as a model system. VAPB is mainly localized to the ER in neuronal cells (Teuling et al., 2007), whereas the distribution of YIF1A in neurons is not clear. Immunofluorescent stainings of HA-YIF1A expressing neurons at 16 days in vitro (DIV16) showed that YIF1A is present in a reticular network throughout the neuron and localizes to discrete puncta in the cell body (Figure 3A). The reticular YIF1A staining partially co-localizes with endogenous VAPB and the ER marker protein disulphide...
isomerase (PDI) (Figure 3B and C). Double labelling with the ERGIC marker ERGIC53/p58 showed partial co-localization in the cell body, indicating that the YIF1A-positive puncta coincide with the ERGIC (Figure 3D). In contrast, the endosome marker early endosomal autoantigen 1 (EEA1) showed no co-localization with HA-YIF1A (Figure 3E).

To further verify the co-localization of YIF1A with the ERGIC, we blocked vesicular trafficking between ER and Golgi using brefeldin A (BFA). Co-stainings with cis-Golgi marker GM130 and ERGIC marker ERGIC53/p58 show respectively little and moderate co-localization with YIF1A in control neurons (Figure 4A, C and E). However, after blocking vesicular trafficking using BFA, YIF1A accumulates in the perinuclear region of the cell body where it strongly co-localizes with Golgi and ERGIC markers (Figure 4B and D).

Analysis of the Pearson’s correlation coefficients of fluorescent signals confirmed that BFA treatment significantly increases the co-localization of YIF1A with Golgi and ERGIC (Figure 4E). In contrast, VAPB is present in the ER, not localized to Golgi and ERGIC structures and its localization is unaffected by BFA treatment (Figure 4F, G and E). These results indicate that while VAPB is restricted to the ER, YIF1A recycles between the Golgi and ER and is predominantly present in the ERGIC.

**VAPB retains YIF1A in the ER and inhibits its recycling into ERGIC and Golgi**

We next determined whether the specific distribution of YIF1A and VAPB depends on each other’s subcellular localization. We generated YIF1A, YIF1B, VAPA and VAPB shRNAs based on the previously published siRNAs sequences to perform knockdown experiments in neurons (Teuling et al, 2007; Carrel et al, 2008). Both VAPA and VAPB shRNAs showed a significant reduction in immunostaining for the respective VAP, indicating an effective knockdown for all VAP-shRNA constructs (Supplementary Figure S2). First, we tested if the VAPB localization in the ER depends on YIF1. In DIV16 neurons, absence of YIF1A/B did not affect the localization of VAPB. Second, we tested if YIF localization depends on VAP using VAPA and VAPB shRNAs. The VAPA/B-shRNA expressing neurons at DIV16 showed a consistent change in YIF1A localization. Whereas control cells have a widespread reticular and punctate YIF1A staining (Figure 5A), VAPA/B knockdown neurons displayed a strong accumulation of YIF1A in the perinuclear region of the cell body (Figure 5B) and a marked co-distribution of YIF1A with cis-Golgi marker GM130 and ERGIC marker ERGIC53/p58. Quantification revealed that the co-localization of YIF1A with GM130 and ERGIC53/p58 is strongly increased in the absence of VAP (Figure 5C–G). These data indicate that knockdown of VAP in neurons leads to a translocation of YIF1A in post-ER structures.

The above data imply that VAPB is important to retain YIF1A in the ER and might control the recycling of YIF1A from the ER to the ERGIC and Golgi. To test this hypothesis, we overexpressed myc-VAPB together with HA-YIF1A. Indeed, YIF1A shows a strong reticular distribution throughout the neuron and loses its characteristic ERGIC localization (Figure 6A, B and D). Next, we tested whether a previously characterized interacting partner of YIF1A, YIP1, also retains YIF1A in the ER. YIP1 has been shown to localize to ER and Golgi membranes as well as coat protein complex II (COPII) transport vesicles in yeast (Yang et al, 1998; Matern et al, 2000; Heidtman et al, 2005; Jin et al, 2005). In hippocampal neurons, Flag-YIP1A has moderate Golgi and a pronounced ERGIC localization (Figure 6C). In contrast to VAPB, Flag-YIP1A overexpression increased YIF1A in the Golgi and ERGIC, while reducing its ER localization, thus having the opposite effect of VAPB (Figure 6C and D). Next, we used fluorescence recovery after photobleaching (FRAP) to examine the mobility of GFP-YIF1A molecules under the influence of increased VAPB levels. A 3-by-3 μm region of the cell soma was bleached by high laser power and fluorescence intensity was measured over a period of ~5 min (Figure 6E). GFP-YIF1A fluorescence recovered rapidly in control neurons and reached a maximal recovery of ~90% within this time frame. In neurons co-expressing myc-VAPB the maximal recovery of GFP-YIF1A is decreased to ~70% (Figure 6E and F), indicating an increase in the immobile fraction of YIF1A molecules in the ER. Taken together, these data suggest that the ER-resident protein VAPB indeed binds YIF1A in the ER and thereby inhibits its recycling to the ERGIC and Golgi.

**YIF and VAP are required for normal dendrite morphology**

Studies in Drosophila neurons and recently in zebrafish suggest that VAPB has an important role in the transport of proteins to the axon (Yang et al, 2012; Forrest et al, 2013) and that loss of VAP proteins affects neuron morphology (Pennetta et al, 2002; Tsuda et al, 2008; Forrest et al, 2013). To assess the morphological effects of depleting YIF1, YIP1 and VAP proteins, we analysed the length of axons and dendrites in hippocampal neurons transfected at DIV1 with VAPA/B-shRNAs, YIF1A/B-shRNAs or YIP1A-shRNA, together with β-galactosidase to visualize neuron morphology (Figure 7A). Neurons were fixed at DIV5 and immunofluorescent staining with antibody against tau was used to distinguish the axon from the dendrites (Figure 7B). Depletion of YIF1 and VAP, but not YIP1, caused a significant decrease in axonal length (Figure 7C). Previous data showed...
that ER-to-Golgi transport is particularly important for dendrite morphology (Ye et al., 2007). Since YIF1, YIP1 and VAP proteins localize to the early secretory pathway in hippocampal neurons we wondered whether depletion of these proteins had any effect on dendrite morphology. Indeed, DIV5 neurons showed a significant decrease in dendritic length when transfected with VAPA/B-shRNAs, YIF1A/B-shRNAs and YIP1A-shRNA (Figure 7D). Because in DIV5 neurons dendrites are short and hardly branched we used mature neurons to examine more closely the effect of
VAP, YIF1 and YIP1 depletion on dendrite morphology. At DIV19, VAPA/B-shRNAs, YIF1A/B-shRNAs and YIP1A-shRNA transfected neurons showed a striking dendritic phenotype (Figure 7E). Quantitative analysis of the pattern of dendritic branching by Sholl analysis (Sholl, 1953) revealed a simplified dendritic tree with reduced branching in proximal dendrites in neurons transfected with VAPA/B-shRNAs, YIF1A/B-shRNAs and YIP1A-shRNA (Figure 7F). The reduced dendritic complexity in the VAPA/B, YIF1A/B and YIP1A knock-down neurons was also revealed by measuring the total dendritic length, counting the number of primary dendrites directly emanating from the soma, and analysing the total number of dendritic tips (Figure 7G–I). Similar results were obtained with independent VAPA, VAPB, YIF1A and YIF1B shRNA sequences (Supplementary Figure S3). In summary, the early secretory pathway components VAPA/B, YIF1A/B and YIP1A are required for normal dendrite morphology in early and later stages of dendrite development.

YIF and VAP are required for intracellular membrane delivery into dendrites

The trafficking of new membrane proteins is essential for normal dendritic growth and morphology (Lecuit and Pilot, 2003). We next determined whether YIF1 and VAP proteins play a role in the delivery of vesicles or cellular material to dendrites. Recent papers show that YIF1B mediates the transport of the serotonin G-coupled receptor (5-HT1A) to dendrites (Carrel et al., 2008; Al Awabdh et al., 2012), however after transfection with VAPA/B-shRNAs or YIF1A/B-shRNAs we do not find changes in YFP-5HT1A receptor localization to mature dendrites (Supplementary Figure S4). Previous studies showed that the small GTPase Sar1, a critical regulator of ER-to-Golgi transport, controls dendritic growth through the delivery of membrane vesicles to dendrites (Ye et al., 2007). We therefore hypothesized that the observed morphological phenotype is caused by a decrease in membrane supply to the dendrites. To see whether VAP and YIF knockdown affect membrane trafficking in primary hippocampal neurons, we employed FRAP experiments. To examine the membrane supply from the soma to the dendrites, we marked membrane with the fluorescent transmembrane protein CD8-GFP (Hoogenraad et al., 2005; Ye et al., 2007). After photo-bleaching one entire dendrite the fluorescence recovery in the same dendrite was monitored immediately over a time period of 20 or 30 min. The fluorescence recovery, due to supply from the soma, in the proximal dendrite (35 μm from the soma) was used for quantifications. In control neurons, CD8-GFP fluorescence recovered to ~70% (Figure 8A, C and D; Supplementary Figure S5). The recovery could be fit with a double exponent (I) with 2 time constants (5) of 36 ± 5 s and 476 ± 15 s (Supplementary Figure S5). To determine the source of GFP-C8D recovery, we conducted several control experiments that indicate that the majority of GFP-C8D recovery depends on intracellular trafficking in the secretory pathway but not on surface diffusion or local protein synthesis (Supplementary Figure S5). Next, we depleted VAP, YIF1 or SAR1 to test whether there is an effect on membrane delivery to dendrites. Sar1-shRNA as well as VAPA/B and YIF1A/B-shRNAs significantly reduced the delivery of CD8-GFP from the soma to the dendrites to ~40–60%, as evident from the recovery curve (Figure 8B and C) as well as the maximal recovery (Figure 8D). These results show that...
VAP and YIF are required for the intracellular delivery of membrane, labelled by CD8-GFP, from soma to dendrites.

**VAPB-P56S traps YIF1A in aggregates and thereby affects its localization**

The P56S mutant form of VAPB is associated with motor neuron disorder ALS8. VAPB-P56S proteins aggregate and form multiple spherical inclusions in cellular and invertebrate model systems. As in COS-7 cells (Figure 1F), HA-YIF1A is recruited to the myc-VAPB-P56S inclusions in neurons (Figure 9A). Consistent with the data that the interaction depends on the transmembrane domain of VAPB-P56S, replacement of this region with a different, unrelated transmembrane domain prevents YIF1A recruitment to VAPB inclusions (Figure 9B). In cells transfected with wild-type VAPB, YIF1A strongly co-localized to the ERGIC after BFA treatment (Figure 4D and 9C). Consistent with the data that the interaction depends on the transmembrane domain of VAPB-P56S, replacement of this region with a different, unrelated transmembrane domain prevents YIF1A recruitment to VAPB inclusions (Figure 9B). In cells transfected with wild-type VAPB, YIF1A strongly co-localized to the ERGIC after BFA treatment (Figure 4D and 9C). Interestingly, in VAPB-P56S expressing cells, YIF1A is absent from the ERGIC structures even after BFA treatment (Figure 9D). These data suggest that when VAPB-P56S is present, YIF1A loses its localization to the ERGIC. In contrast, the YIF1A binding protein Flag-YIP1A and YPF-ERGIC53/p58 do not co-localize with these VAPB-P56S/YIF1A-positive aggregates (Figure 9E–H).

The MSP domain in VAP proteins binds to the ‘two phenylalanines in an acid tract’, or ‘FFAT’ motif found in several cytoplasmic lipid-binding proteins, including OSBPL9 and NIR2 (Kaiser et al., 2005; Loewen and Levine, 2005; Teuling et al., 2007). In this way, VAP proteins may act as docking sites for cytoplasmic factors to interact with the ER, coordinate lipid transfer between ER and Golgi apparatus or maintain the structure of the ER by interacting with the cytoskeleton (Amarilio et al., 2005; Peretti et al., 2008; Ngo and Ridgway, 2009). It was recently shown that the P56S substitution in VAPB induces conformational changes within the MSP domain and perturbs FFAT-motif binding (Teuling et al., 2007; Kim et al., 2010). Consistent with these results, FFAT-motif containing proteins OSBPL9 and NIR2 are absent from YIF1A-positive VAPB-P56S aggregates in neurons (Supplementary Figure S6). Together, these results suggest that both perturbation of FFAT-dependent association with the ER and mislocalization of YIF1A could contribute to the pathological mechanisms observed in ALS8.

**Discussion**

In this study, we identified YIF1A as a new VAPB binding partner and we showed that, in contrast to other VAPB interaction partners, YIF1A does not bind to the MSP domain of VAPB, but via its transmembrane domain interacts with the transmembrane domain of VAPB. In hippocampal neurons, we showed that VAPB–YIF1A interaction controls the shuttling of YIF1A between the ERGIC and the ER and plays an important role in early secretory events in neurons, promoting membrane trafficking and normal dendritic growth. In addition, we show that YIF1A in contrast to other VAPB interaction partners also binds ALS8-mutant VAPB and co-accumulates in abnormal ER-derived structures. We propose that the mislocalization of YIF1A into VAPB-P56S aggregates could contribute to pathological mechanisms observed in VAPB-associated motor neuron diseases.
YIF1A interacts with VAPB in the early secretory pathway

VAPB has been implicated in multiple cellular functions, either as a conserved ER anchoring protein or as a secreted signalling molecule in invertebrates (Lev et al., 2008; Han et al., 2012). Proteins with an FFAT or an FFAT-like motif that can bind the FFAT-motif binding site in the MSP domain of VAPA and VAPB represent a major group of VAPB interacting proteins. FFAT-motif proteins include oxysterol binding proteins (OSBPs), OSBP-related proteins (ORPs) and NIR proteins (Wyles and Ridgway, 2004; Amarilio et al., 2005; Loewen and Levine, 2005; Kawano et al., 2006) and have been shown to play a role in ER structure (Wyles et al., 2002; Amarilio et al., 2005; Lehto et al., 2005) and the transport of membrane lipids (Kawano et al., 2006; Peretti et al., 2008). Other proteins with FFAT-like motifs include for instance PKA anchoring proteins that could play a role in cAMP signalling on the ER (Mikitova and Levine, 2012). In addition, an outer mitochondrial membrane protein (PTPIP51) was shown to interact with VAPB (De Vos et al., 2012) putatively via FFAT-

Figure 5 Effect of VAP knockdown on YIF1A localization in cultured hippocampal neurons. (A, B) Representative images of cell bodies of hippocampal neurons co-transfected at DIV16 for 4 days with HA-YIF1A (red), GFP and pSuper control vector (A) or pSuper-VAPA and pSuper-VAPB shRNAs (B). VAP knockdown results in relocalization of HA-YIF1A. (C–F) Cell bodies of neurons co-transfected with HA-YIF1A (red) and pSuper control vector (C, E) or pSuper-VAPA and pSuper-VAPB shRNAs (D, F). Neurons were stained for either GM130 (C, D) or ERGIC53/p58 (E, F). Solid lines indicate the cell edges. Scale bar, 5 μm. (G) Summary of co-localization experiments. Pearson’s coefficient (r_p) for YIF1A versus ERGIC53/p58 and GM130 in control (black bars) and VAP knockdown neurons (white bars). Seventeen to twenty-three ROIs were analysed for each condition. Error bars indicate s.e.m., ***P<0.001.
like motifs, although the basis for this interaction was not studied (Mikitova and Levine, 2012). In contrast to the previously described VAP binding partners, the interaction with YIF1 occurs via the transmembrane domain, although we cannot fully exclude a role for the cytosolic VAPB domain. During submission of this paper, another study reported a similar transmembrane mediated interaction between Drosophila VAP and Sac1, a phosphoinositide phosphatase (Forrest et al., 2013). YIF1A and YIF1B in mammals are homologous to Yif1p in yeast. Yif1p is located to the Golgi membrane and COPII vesicles, forms a tight complex with its family member Yip1p and plays an important role in early secretory transport in yeast (Entian et al., 1999; Matern et al., 2000; Otte et al., 2001). Cell-free assays and thermosensitive yeast strains demonstrated that Yif1p and Yip1p play a critical role in the biogenesis of ER-derived COPII transport vesicles (Barrowman et al., 2003; Heidtman et al., 2005). Recent genome-wide RNA interference screens in Drosophila S2 and HeLa cells found that depletion of YIF1 or YIP1 inhibits secretion, indicating that YIF1/YIP1 are functionally conserved components of the secretory pathway (Wendler et al., 2010; Simpson et al., 2012). We find that YIF1A is predominantly localized to the ERGIC and recycles between the ER and Golgi in hippocampal neurons. In agreement with these results, proteomics analysis identified YIF1A in ERGIC-enriched membranes (Breuza et al., 2004) and BFA treatment of HeLa cells results in YIF1A accumulations in the ERGIC (Yoshida et al., 2008). Our data indicate that both VAPB and YIF1A are needed for an efficient transition of membrane cargo through the early secretory pathway in neurons.

Figure 6 VAPB overexpression relocalizes YIF1A. (A–C) Hippocampal neurons transfected with HA-YIF1A and stained with anti-HA (green) and anti-ERGIC53/p58 (blue). Co-transfection with either myc-VAPB (B) or FLAG-YIP1A (C) results in relocalization of HA-YIF1A. Solid lines indicate the cell edges and panels on the right side show enlargements of the boxed regions. Scale bar, 5 μm. (D) Summary of co-localization experiments. Pearson’s coefficient ($r_p$) for YIF1A versus ERGIC53/p58 and GM130 in control (black bars), VAPB overexpressing (red bars) and YIP1A overexpressing neurons (white bars). Thirteen to twenty-three ROIs were analysed for each condition. (E) Fluorescent recovery plots showing the rates of GFP-YIF1A recovery in cell bodies of control neurons and neurons overexpressing VAPB. Fluorescent intensity was normalized to intensity before bleaching. $P = 0.008$; repeated measures ANOVA. (F) Histogram representing the maximal recovery of fluorescence (estimated mobile fraction) in hippocampal neurons expressing GFP-YIF1A with ($n = 11$) or without VAPB overexpression ($n = 10$). Data are presented as means ± s.e.m., *$P < 0.05$, ***$P < 0.001$. 

VAPB and YIF1A function in the early secretory pathway

M Kuipers et al
Figure 7 YIF1 and VAP are required for normal dendrite morphology. (A) Hippocampal neurons co-transfected at DIV1 with indicated constructs and β-galactosidase to visualize morphology. (B) Representative image of a hippocampal neurons (DIV5) co-transfected with empty pSuper and β-galactosidase and co-stained with Tau (green) to highlight the axon. (C, D) Quantification of total axonal length and dendritic length after 4 days overexpression of knockdown constructs or empty pSuper as control (14–16 cells were analysed for each condition). (E) Hippocampal neurons co-transfected at DIV15 with indicated constructs and β-galactosidase to visualize morphology. (F) Sholl analysis and quantification of the total dendritic length (G), number of primary dendrites (H) and dendritic tips (I) after 4 days overexpression of knockdown constructs or empty pSuper as control (15–17 cells were analysed for each condition). Error bars indicate s.e.m., **P<0.01, ***P<0.001. Scale bars represent 50 μm.
Furthermore, we show that, while YIF1A is cycling between ER and Golgi, VAPB is restricted to the ER and is not present in ERGIC or Golgi, indicating that YIF1A-VAPB binding is most likely to occur in the ER membrane (Supplementary Figure S7). We hypothesize that YIF1A is retained in the ER membrane by its interaction with VAPB which subsequently allows specific membrane lipids and/or cargo proteins to concentrate at ERES before budding off in carriers destined for further transport towards the ERGIC and cis-Golgi membrane (Gurkan et al., 2006; Jensen and Schekman, 2011).

Moreover, interactome analyses in yeast revealed that the Yip1p/Yif1p family proteins associate with a large range of gene products that function in the vesicular transport pathway, including SNAREs, Rab GTPases, ARF-GAP and sorting nexins (Ito et al., 2000; Uetz et al., 2000). Future studies using cell-free assays driven by purified proteins that recapitulate protein transport between the ER and the Golgi complex will help to elucidate the mechanisms regulating the interplay between VAP, YIF1A and the other components of the ER-to-Golgi trafficking pathway and advance our understanding of the biogenesis of transport carriers in the early secretory transport.

**YIF and VAP are required for intracellular membrane delivery into dendrites**

The early secretory pathway is fundamentally important for neuronal development and function (Hanus and Ehlers, 2008; Tang, 2008; Aridor and Fish, 2009; Jan and Jan, 2010), and some lines of evidence suggest that the organization of secretory trafficking in neurons differs in several ways from the pathways in non-neuronal cells (Nelson and Yeaman, 2001; Stephens and Pepperkok, 2001; Tang, 2008). In particular components of the ER, ERGIC and Golgi have been identified in dendrites, specifically localizing at branch points and close to dendritic spines (Krijnse-Locker et al., 1995; Pierce et al., 2001; Horton et al., 2005; Appenzeller-Herzog and Hauri, 2006). Here, we identify VAPB and YIF1A as early secretory trafficking components that are required for membrane transport and important for normal dendrite morphology. First, we showed that VAPB is able to retain YIF1A in the ER thereby regulating its recycling to ERGIC and Golgi. Depletion of VAP proteins results in a relocation of ERGIC protein YIF1A to the Golgi, indicating that VAPB regulates trafficking of YIF1A through the ERGIC. Recent studies showed that disruption of VAP affects ER-to-Golgi transport and anterograde VSVG trafficking in HeLa cells (Peretti et al., 2008; Rao et al., 2012). Second, depletion of VAP, YIF1 as well as YIP1 affects dendrite morphology. This is consistent with the observed dendritic phenotype in secretory trafficking deficient Drosophila mutants (Ye et al., 2007). Third, we show that both VAPA/B and YIF are required for a normal membrane supply to dendrites, indicating that the observed effect on dendrite morphology is caused by a defect in early secretory trafficking. The fact that other proteins of the ER-to-Golgi trafficking pathway, such as Sar1, also affect dendritic growth and membrane trafficking (Ye et al., 2007) strengthens the model that VAPB and YIF1A have an important role in the secretory transport. Interestingly, YIF1B has been shown to play a role in the neuronal ER-Golgi trafficking machinery by specific targeting the serotonin G-coupled receptor (5-HT1A) to dendrites (Carrel et al., 2008). A recent follow-up study proposed that YIF1B acts as a scaffolding complex that recruits 5-HT1A together with YIP1A and Rab6 in dendritic transport vesicles (Al Awabdh et al., 2012). These results imply that at least YIF1B and...
VAPB and YIF1A function in the early secretory pathway

M Kuijpers et al
possibly other Yip1p/Yif1p family proteins play a role in the anterograde transport of a limited subset of cargo molecules from the ER to the Golgi. Although in our study we do not find evidence that YIF1 or VAP plays a role in the transport of the serotonin receptor we believe that defects in the transport of specific proteins under the influence of VAP or YIF impairments are difficult to measure as other, unconventionally, transport routes can be used as default (Grieve and Rabouille, 2011).

**YIF1A and ALS8**

The P56S mutation in the gene encoding VAPB causes ALS8 and some other related forms of motor neuron disease (Nishimura et al, 2004). Several studies already showed that VAPB-P56S induces the formation of abnormal ER-derived inclusions, perturbs ER–Golgi trafficking and triggers ER stress (Nishimura et al, 2004; Teuling et al, 2007; Tsuda et al, 2008; Suzuki et al, 2009; Chen et al, 2010; Fasana et al, 2010; Moumen et al, 2011). Ubiquitin (Moumen et al, 2011) and BAP31 (Fasana et al, 2010) have been described to accumulate in the VAPB-P56S clusters, suggesting that mutant VAPB-induced aggregation is part of the ER-associated degradation pathway. Mutant VAPB-P56S also induces the co-aggregation of wild-type VAPB, suggesting a dominant-negative mode of pathogenesis (Teuling et al, 2007). Disruption of ER and Golgi structure and function has previously been suggested as a possible pathological mechanism for neurodegenerative diseases (Mourelatos et al, 1996; Lehotsky et al, 2003; Paschen and Mengersdorf, 2005; Vlug et al, 2005; Yoshida, 2007). How VAPB-P56S disrupts protein trafficking between the ER and Golgi and how this may lead to the pathogenesis of ALS8 is not yet understood. The identification of the VAPB–YIF1A interaction and its role in early secretory transport raises the possibility that YIF1A might be involved in the development of neurodegenerative diseases. Both YIF1A and YIF1B are ubiquitously expressed in the CNS (Carrel et al, 2008) and a microarray analysis showed downregulation of YIF1A in motor neurons isolated from the spinal cord of SOD1-G93A transgenic mice, a model for familial ALS (Ferraiuolo et al, 2007). This suggests that YIF1A could be a potential factor involved in the multi-factorial causes leading to ALS. Although the relevance of our observations to heterozygous patients remains uncertain (as our observations are under overexpression conditions), our model suggests that mislocalization of YIF1A to aggregates leads to a defect in secretory trafficking and a subsequent inhibition of dendritic growth and maintenance. Defects in neuronal secretory trafficking already have been shown to affect dendritic growth (Horton et al, 2005; Ye et al, 2007). Dendritic alterations have been documented in mouse models for motor neuron dysfunction (Wiggins et al, 2012) and in ALS-affected patients (Liu et al, 2011). In patients, dendrites in anterior horn cells are shorter and thinner, or are lost (Kato et al, 1988; Sasaki and Iwata, 1996). Moreover, loss and atrophy of dendrites was found in motor neurons in the spinal cord (Karpati et al, 1988). Similarly, in presymptomatic SOD1-G93A transgenic mice dendrites in the motor cortex show signs of degeneration and in the prefrontal cortex a reduction in the length of basal dendrites and branch points was observed (Sgobio et al, 2008; Jara et al, 2012). Changes in dendritic architecture are indicative of defects in neuronal function and connectivity, and could be contributing to the development of sites of degeneration. Though there is overwhelming evidence for axonal transport dysfunctions in the pathogenesis of ALS (Chevalier-Larsen and Holzbaur, 2006; Sau et al, 2011), our study indicates that alterations in dendritic structure and trafficking may also play an important role in neurodegeneration. A recent study has reported mild late onset motor deficits in VAPB-deficient mice in the absence of axonal and neuromuscular junction abnormalities (Forrest et al, 2013). Whether these mice develop dendritic abnormalities and the degree of compensation of VAPB deficiency by VAP in these mice requires further investigation.

In conclusion, we have identified YIF1A as a novel binding partner of VAPB and established a key role for these proteins in the neuronal early secretory pathway. We found that both VAP and YIF1 proteins are important for proper membrane trafficking and normal dendritic growth. Moreover, the ALS-linked mutant VAPB-P56S recruits YIF1A to aggregates and disrupts its normal localization to ERGICs. Understanding the cellular function of VAPB may indicate what molecular and cellular events are associated with the disease process of ALS8. Our current findings provide new molecular targets to investigate VAPB-linked neurodegeneration. It is likely that this information will be of relevance to both the inherited condition and the more common sporadic forms of disease.

**Materials and methods**

**Expression constructs and shRNA**

The following mammalian expression plasmids have been described previously: bio-HA-VAPB, GFP-VAPB-TMD, GFP-VAPB, HA- and myc-tagged VAPA, VAPB and VAPA/B-P56S constructs (Teuling et al, 2007), protein-biotin ligase BirA (Lansbergen et al, 2006), flag-YIF1B (Carrel et al, 2008), flag-YIF1A (Dykstra et al, 2010), ERGIC/p58-YFP (Ward et al, 2001) and CD8-GFP (Hoogenraad et al, 2005). Bio-GFP-VAPB, Bio-HA-VAPB-P56S and Bio-HA-VAPB were generated by incorporating a biotinylation-tag (MSGLNDFEAQKIEWHE) before the GFP- or HA-tagged mutant or wild-type VAPA/B construct. VAPB-P56S-CDSTM was made by removing the transmembrane domain of VAPB-P56S and adding the transmembrane domain of CD8 with a PCR-based strategy using HA-VAPB-P56S and GFP-CD8 as a template and subcloned into a pJfactin expression vector. Full-length and truncated human YIF1A constructs were generated by PCR using IMAGE clone 3451489 as template and cloned into HA- and GFP-tagged pGW1-expression vectors. For bio-GFP-YIF1A, a biotinylation tag was inserted in front of the pEGFP-C2 (Clontech) and the YIF1A openreading frame subsequently subcloned in the biotin-tag-GFP vector. GFP-YIF1A lxxxl was generated from GFP-YIF1A by introducing G154I, G158I, and IxxxI was generated from GFP-YIF1A by introducing G154I, G158I, IxxxI was generated from GFP-YIF1A by introducing G154I, G158I, IxxxI was generated from GFP-YIF1A by introducing G154I, G158I,
complementary oligonucleotides were annealed and inserted into a pSuper vector (Brummelkamp et al., 2002). Unless otherwise specified, all VAP and YIF shRNAs presented in the paper refer to shRNAs#1.

**Antibodies and reagents**

The following antibodies were used for immunocytochemistry: rabbit-anti-VAPB and rabbit-anti-VAPA (1:500) (Teuling et al., 2007); NIB2 (1:500) (Litvak et al., 2004), OSBP19 (1:600) (Nigo and Ridgway, 2009); human-anti-EAA1 (1:500) (Selak et al., 2000). The following antibodies were obtained from commercial sources: mouse-anti-tau (1:500, Chemicon); mouse-anti-disulphide isomerase (PDI; 1:500, Affinity BioReagents); mouse-anti-GM130 (1:1000, BD Biosciences); mouse-anti-HA (1:500, Roche); mouse-anti-MAP2 (1:2000, Sigma); mouse-anti-myc (1:200, Santa Cruz Biotechnology); mouse-anti-flag (1:2000, Sigma); rabbit-anti-ERGIC53/p58 (1:200, Sigma); rabbit-anti-HA (1:500; Santa Cruz Biotechnology); rabbit-anti-flag (1:200, Sigma); rabbit-anti-myc (1:200; Cell Signaling Technology); rabbit-anti-Bgalactosidase (1:2000, MP Biomedicals); rat-anti-HA (1:200, Roche); mouse-anti-CDB (1:20, Mabtech); Alexa Fluor 488-, Alexa Fluor 594-, and Alexa Fluor 633-conjugated secondary antibodies (1:400, Invitrogen) and Cy5-conjugated secondary antibody (1:400, Jackson ImmunoResearch Labs). The following antibodies were used for western blot analysis: rabbit anti-GFP (1:1000, Abcam); rabbit anti-HA (1:500, Santa Cruz); mouse anti-HA (1:500, Covance) and HRP-conjugated secondary antibodies (1:5000, Dako). BFA and cycloheximide were obtained from Sigma.

**Transfection and immunofluorescence of cultured COS-7 cells**

COS-7 cells were cultured in DMEM/Hams F10 (50/50%) medium containing 10% FCS and 1% penicillin/streptomycin. Two days before transfection, cells were plated at 130 in Lab-tek chamber slides (Nunc). Cells were transfected with Fugene 6 (Roche) according to manufacturer's protocol and incubated overnight. Cells were fixed in 4% paraformaldehyde for 10 min at room temperature followed by 5 min in 1% Triton X-100 in PBS. Slides were blocked in 0.5% BSA/0.02% glycine in PBS and labelled with primary antibody for 2 h at room temperature. Slides were washed three times with 0.05% Tween-20 in PBS, labelled with secondary antibodies for 1 h at room temperature, washed three times with 0.05% Tween-20 in PBS and mounted using Vectashield mounting medium (Vector laboratories). Images were acquired using a Leica DMRB8 microscope equipped with ×40 and ×100 oil objectives.

**Animals**

All animal experiments were performed in compliance with the guidelines for the welfare of experimental animals issued by the Federal Government of The Netherlands. All animal experiments were performed in compliance with the guidelines for the welfare of experimental animals issued by the Federal Government of The Netherlands. All animal experiments were performed in compliance with the guidelines for the welfare of experimental animals issued by the Federal Government of The Netherlands.

**Hippocampal neuron cultures, transfection and immunohistochemistry**

Primary hippocampal cultures were prepared from embryonic day 18 (E18) rat brains (Banker and Goslin, 1988; Kapitein et al., 2004). Cells were plated on coverslips coated with poly-L-lysine (35 µg/ml) and laminin (5 µg/ml) at a density of 75,000/well. Hippocampal cultures were grown in Neurobasal medium (NB) supplemented with B27, 0.5 mM glutamine, 12.5 µM glutamate and penicillin/streptomycin. Hippocampal neurons were transfected using Lipofectamine 2000 (Invitrogen). Briefly, DNA (3.6 µg/ml) was mixed with 3 µl of NB, incubated for 30 min, and then added to the neurons in NB at 37°C in 5% CO2 for 45 min. Next, neurons were washed with NB and transferred in the original medium at 37°C in 5% CO2. After 2–4 days of transfection, neurons were fixed with 4% paraformaldehyde/4% sucrose in PBS, washed three times in PBS for 10 min and incubated with the indicated primary antibodies in GDB buffer (0.2% BSA, 0.8 M NaCl, 0.5% Triton X-100, 30 mM phosphate buffer, pH 7.4) overnight at 4°C. Neurons were then washed three times in PBS for 30 min, incubated with secondary antibodies in GDB for 1 h at room temperature and washed three times in PBS for 30 min. Slides were mounted using Vectashield mounting medium (Vector Laboratories). Confocal images were acquired using a Leica microscope equipped with a ×100 oil objective. Confocal images were acquired using a LSM510 confocal microscope (Zeiss) with a ×40 or ×63 oil objective.

**Immuno precipitation**

HER293T cells were cultured in DMEM/Hams F10 (50/50%) medium containing 10% FCS and 1% penicillin/streptomycin and were transfected using Lipofectamine2000 (Invitrogen). Cells were harvested 24 h after transfection, by scraping the cells in ice-cold PBS and lysing cell pellets in lysis buffer (50 mM Tris–HCl, 100 mM NaCl, 1.0% Triton X-100 and protease inhibitors (Roche). Supernatant and pellet fractions were separated by centrifugation at 13,200 r.p.m. for 5 min. Supernatants were mixed with an equal amount of lysis buffer, protein-A-agarose beads (GE Healthcare), and 3 µg of rabbit anti-GFP, mouse anti-HA or control IgG (Sigma). Samples were incubated 4 h while rotating at 4°C, centrifugated at 2000 r.p.m. and pellets were washed three times with lysis buffer. Samples were mixed with 4 × Sample Buffer (8% SDS, 25% Glycerol, 0.05 M Tris pH 6.8, 200 mM DTT, 40 mg/l Bromophenol Blue) and boiled. Equal amounts of protein were loaded onto SDS–PAGE gels and subjected to western blotting on polyvinylidene difluoride membrane. Blots were blocked with 2% bovine serum albumin/0.05% Tween-20 in PBS and incubated with primary antibodies at 4°C overnight. Blots were washed with 0.05% Tween-20 in PBS three times for 10 min at room temperature and incubated with secondary antibodies conjugated to horseradish peroxidase (Dako). Blots were developed with enhanced chemiluminescent Western blotting substrate (Pierce).

**GST pull-down**

Full-length wild-type and mutant VAPB GST fusion proteins were obtained as described earlier (Teuling et al., 2007). HER293T cells were transfected as described before with HA-YIF1A (1–131), HA-YIF1A (131–193) and HA-YIF1A (198–293) and lysed in 50 mm Tris–HCl, 100 mm NaCl, and 1% Triton X-100 containing protease inhibitors (Roche). Lysates were incubated with GST beads (GE Healthcare Bio-Sciences) for 2 h at 4°C, washed four times with lysis buffer, and analysed by SDS–PAGE and western blotting as described below.

**Biotin-streptavidin pull-down and mass spectrometry**

For biotin-streptavidin pull-down assays, HeLa or HER293T cells were transfected with biotin-tagged VAPB using Lipofectamine-2000 (Invitrogen) transfection reagent according to manufacturer's instructions. Cells were lysed 16 h later in 20 mm Tris–HCl, pH 8.0, 150 mM KCl, 1% Triton X-100, and protease inhibitors (Roche). To increase the solubility of VAPB-PSiS, transfected cells were incubated for 2 h at 37°C before lysis. Cell lysates were centrifuged at 13,000 r.p.m. for 15 min and the supernatants were incubated with Dynabeads M-280 streptavidin (Dynal; Invitrogen) for 45 min. Beads were separated by using a magnet (Dynal; Invitrogen) and washed five times in lysis buffer. For protein elution, the beads were boiled in NuPAGE LDS 4 sample buffer (Invitrogen), separated, and supernatants were run on a 10% NuPAGE Bis-Tris gel (Invitrogen). The gel was stained with the Colloid Blue staining kit (Invitrogen) and bands were visualized by Western blotting. Mass spectrometry was performed as described previously (Lansbergen et al., 2006). The Mascot score cutoff value for a positive protein hit was set to 100. Individual peptide tandem mass spectrometry spectra with Mascot scores below 100 were checked manually and either interpreted as valid identifications or discarded. Proteins present in the negative controls (pull-down assays with bio-GFP alone) were regarded as background.

**Photobleaching experiments**

For quantitative FRAP experiments, neurons were transfected as described before, and imaged on a Nikon Eclipse TE2000E (Nikon) equipped with an incubation chamber (INU2-ZILCS-H2; Tokai Hit) mounted on a motorized stage (Prior) (Jaworski et al., 2009). Coverslips (24 mm) were mounted in metal rings and maintained at 37°C and 5% CO2 for 2 h and 3 × 3 min by photobleaching. Mass spectrometry was performed as described previously (Lansbergen et al., 2006). The Mascot score cutoff value for a positive protein hit was set to 100. Individual peptide tandem mass spectrometry spectra with Mascot scores below 100 were checked manually and either interpreted as valid identifications or discarded. Proteins present in the negative controls (pull-down assays with bio-GFP alone) were regarded as background.
Image analysis and quantification

Measurement of neurite outgrowth. To measure neurite length, we used β-galactosidase as an unbiased cell-fill. Hippocampal neurons were transfected with the indicated constructs, fixed at the appropriate time point and subjected to immunofluorescent staining. Confocal images were obtained at 1024 × 1024 pixel resolution using a LSM510 confocal microscope (Zeiss) with a × 40 oil objective (0.7 digital zoom). Each image was a z-series of images; the obtained stack was ‘flattened’ into a single image using maximum projection. Morphometric analysis and quantification were performed using MetaMorph image analysis software (Universal Imaging). For measurement of total dendrite or axonal length, all dendrites or axons of individual neurons were traced. All non-axonal protrusions initiating from the cell soma longer than 10 μm were defined as primary dendrites. For dendrite tip number, tips of all non-axonal protrusions longer than 10 μm were counted. For Sholl analysis, concentric circles with 16 μm differences in diameter were automatically drawn around the cell body, and the number of dendrites crossing each circle was counted.

Co-localization of two fluorescent signals. Co-localization of two fluorescent signals was indicated by the Pearson’s coefficient (r), determined using the JACoP plugin (Bolte and Cordelières, 2006) for ImageJ. For each cell, three ROIs were selected; r was defined as the number of ROIs.

Statistical analyses

Statistical analyses were performed with MS Excel or SPSS software. Data were averaged over multiple cells and statistical analysis was performed with Student’s t-test, one-way ANOVA or repeated measures ANOVA and Tukey’s post hoc test. P < 0.05 was considered as significant.

References


Heidtman M, Chen CZ, Collins RN, Barlowe C (2005) Yoslp1 is a novel subunit of the Yot1p-Yot1p complex and is required for transport between the endoplasmic reticulum and the Golgi complex. Mol Biol Cell 16: 1673–1683


Krijnse-Locker J, Porton RC, Fuller SD, Griffiths G, Dotti CG (1995) The organization of the endoplasmic reticulum and the inter-


stress-related death by inducing aggregation of co-expressed wild-type VAPB. J Neurochem 108: 973–985


The EMBO Journal VOL 32 | NO 14 | 2013 ©2013 European Molecular Biology Organization